Comparison 1. n‐3 LCPUFA supplementation versus placebo or no supplementation ‐ any allergy.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Any allergies (with sensitisation): medically diagnosed IgE mediated	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
1.1 Up to 12 months	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 12 to 36 months	2	823	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.44, 0.98]
1.3 Beyond 36 months	1	706	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.61, 1.20]
2 Any allergies (+/‐ sensitisation): medically diagnosed/parental reported	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Up to 12 months	0	0	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2.2 12 to 36 months	2	823	Risk Ratio (M‐H, Fixed, 95% CI)	0.89 [0.71, 1.11]
2.3 Beyond 36 months	3	1765	Risk Ratio (M‐H, Fixed, 95% CI)	0.96 [0.84, 1.09]